World's Best Scientists 2026 revealed!
Aimery de Gramont

Aimery de Gramont

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 73 19531 18327 660 625 385 35066

Aimery de Gramont publications per year

The chart shows the history of publications by Aimery de Gramont between 1982 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Aimery de Gramont published across 44 years, from 1982 to 2025, averaging 11.1 papers a year. Output peaked at 66 publications in 2024. 72 of the 490 publications appeared in the last two years.

No. of publications
20 40 60
Bar chart. Horizontal axis: year, 1982 to 2025. Vertical axis: number of publications, 0 to 66. Peak 66 publications in 2024. 1982: 1 publication 1983: 0 publications 1984: 0 publications 1985: 7 publications 1986: 3 publications 1987: 6 publications 1988: 3 publications 1989: 2 publications 1990: 0 publications 1991: 4 publications 1992: 5 publications 1993: 2 publications 1994: 0 publications 1995: 1 publication 1996: 1 publication 1997: 4 publications 1998: 1 publication 1999: 1 publication 2000: 4 publications 2001: 6 publications 2002: 6 publications 2003: 8 publications 2004: 14 publications 2005: 7 publications 2006: 15 publications 2007: 14 publications 2008: 4 publications 2009: 17 publications 2010: 16 publications 2011: 23 publications 2012: 17 publications 2013: 20 publications 2014: 24 publications 2015: 22 publications 2016: 17 publications 2017: 12 publications 2018: 26 publications 2019: 13 publications 2020: 16 publications 2021: 21 publications 2022: 17 publications 2023: 38 publications 2024: 66 publications 2025: 6 publications
1982 2025

490 publications in total across all disciplines

View publications per year as a table
Aimery de Gramont: publications per year, 1982 to 2025
Year Publications
1982 1
1983 0
1984 0
1985 7
1986 3
1987 6
1988 3
1989 2
1990 0
1991 4
1992 5
1993 2
1994 0
1995 1
1996 1
1997 4
1998 1
1999 1
2000 4
2001 6
2002 6
2003 8
2004 14
2005 7
2006 15
2007 14
2008 4
2009 17
2010 16
2011 23
2012 17
2013 20
2014 24
2015 22
2016 17
2017 12
2018 26
2019 13
2020 16
2021 21
2022 17
2023 38
2024 66
2025 6
Total 490
Download as CSV

Aimery de Gramont publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Aimery de Gramont sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 381–400 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 385 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861 385
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Aimery de Gramont D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Aimery de Gramont sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 72–73 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 73 D-Index — 3rd percentile

3% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391 73
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Aimery de Gramont is affiliated with Grenoble Alpes University in France and has made significant contributions to the field of medicine, focusing primarily on oncology. Their research encompasses various aspects of cancer treatment and associated diagnostics, with a strong emphasis on colorectal and gastric cancers.

Their scholarly output features numerous publications in respected venues. Frequent publication outlets include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • JNCI Journal of the National Cancer Institute
  • UNC Libraries

Aimery de Gramont's recent papers reflect ongoing clinical and translational research in colorectal cancer. Among these are:

  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, 2023, Journal of Clinical Oncology
  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials, 2020, Journal of Clinical Oncology
  • Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone, 2021, Cancer Treatment Reviews
  • Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial, 2021, Clinical Cancer Research
  • Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database, 2020, JNCI Journal of the National Cancer Institute

Frequent co-authors collaborating with Aimery de Gramont include:

  • Qian Shi
  • Takayuki Yoshino
  • Thierry André
  • Benoist Chibaudel
  • John Zalcberg

Their research covers major topics within oncology, particularly:

  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Surgical Treatments
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics

Main areas of study reflect a broad approach to cancer research with primary focus areas including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Surgery
  • Cancer Research

Best Publications

  • Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

    Thierry Andre;Corrado Boni;Lamia Mounedji-Boudiaf;Matilde Navarro

  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

    Christophe Tournigand;Thierry André;Emmanuel Achille;Gérard Lledo

  • Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

    Thierry Andre;Corrado Boni;Matilde Navarro;Josep Tabernero

  • OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

    Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors

    Gérard Socié;Jean-Yves Mary;Aimery de Gramont;Bernard Rio

  • Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

    Thierry André;Armand De Gramont;Dewi Vernerey;Benoist Chibaudel

  • Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan

  • Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

    Florence Huguet;Thierry André;Pascal Hammel;Pascal Artru

  • The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus

    René Adam;Aimery De Gramont;Joan Figueras;Ashley Guthrie

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

    René Adam;Aimery de Gramont;Joan Figueras;Norihiro Kokudo

  • Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer

    Richard M. Goldberg;Isabelle Tabah-Fisch;Harry Bleiberg;Aimery de Gramont

  • Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

    Benoist Chibaudel;Frédérique Maindrault-Goebel;Gérard Lledo;Laurent Mineur

  • Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

    Christophe Tournigand;Thierry André;Franck Bonnetain;Benoist Chibaudel

  • Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

    Demetris Papamichael;R. A. Audisio;B. Glimelius;A. de Gramont

  • Biomarkers and surrogate end points—the challenge of statistical validation

    Marc Buyse;Daniel J. Sargent;Axel Grothey;Alastair Matheson

  • Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

    Thierry André;Mohamed A. Bensmaine;Christophe Louvet;Eric François

  • Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

    Josep Tabernero;Eric Van Cutsem;Eduardo Díaz-Rubio;Andrés Cervantes

Frequent Co-Authors

Thierry André
Thierry André Université Paris Cité
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Julien Taieb
Julien Taieb Université Paris Cité
John R. Zalcberg
John R. Zalcberg Monash University
Marc Buyse
Marc Buyse Hasselt University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn't always require the traditional path of attending medical school. There are various online degree options that can prepare you for rewarding roles within the healthcare sector. For those interested in healthcare leadership, exploring online mha programs affordable can provide a cost-effective route to management positions.

If you’re aiming to advance your nursing credentials, consider enrolling in one of the cheap online dnp programs. These programs can open doors to advanced clinical or academic positions while offering the flexibility of online study.

Pharmacy is another growing field, and several online pharmacist programs now make it more accessible than ever to earn a recognized qualification from home.

For those interested in the intersection of healthcare and technology, earning a bachelor of health information management online can lead to a career managing the vital flow of health data in medical organizations.

These online pathways offer flexibility, affordability, and opportunities to enter or advance in healthcare without following the traditional physician track.

Best Scientists Citing Aimery de Gramont

Trending Scientists

Recently Published Articles